



UNIVERSITY OF LEEDS

This is a repository copy of *Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease.*

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/138254/>

Version: Accepted Version

---

**Article:**

Dubash, S, Marianayagam, T, Tinazzi, I et al. (12 more authors) (2018) Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. *Rheumatology*, Key 26. ISSN 1462-0324

<https://doi.org/10.1093/rheumatology/key267>

---

Copyright © 2018, Oxford University Press. This is a pre-copyedited, author-produced version of an article accepted for publication in *Rheumatology* following peer review. The version of record, Dubash, S, Marianayagam, T, Tinazzi, I et al. (12 more authors) (2018) Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. *Rheumatology*, Key 26 is available online at: <https://doi.org/10.1093/rheumatology/key267>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Patient number	1	2	3	4	5	6	7	8	9	10	11
Age, M/F	28, M	48, M	33, F	50, M	35, F	40, F	21, F	52, M	45, F	44, F	72, M
Hospitalised	Y	N	N	N	Y	Y	N	N	Y	N	N
Vedolizumab exposure (weeks)	14	20	20	6	8	10	5	12	4	52	20
Pre-existing SpA	Y	N	N	N	N	N	N	N	Y	N	N
axSpA	Y	Y	Y	Y	Y	N	Y	N	Y	Y	N
perSpA	Y	Y	N	N	N	Y	Y	Y	Y	Y	Y
Osteitis or Enthesitis	+++	++	++	+++	NA	++	++	+++	+++	+++	+++
MRI/USS (imaging feature)	<u>MRI:</u> Extreme Perifacetal spinal vertebral oedema	<u>MRI:</u> Bilateral sacroiliitis	<u>MRI:</u> Bilateral sacroiliitis	<u>MRI:</u> Extensive severe thoraco-lumbar vertebral oedema/osteitis and IRLs	<u>MRI</u> -ve, nr-axSpA	<u>MRI:</u> Enthesitis/p eriosittis distal tibio-fibular	<u>MRI:</u> Right sided sacroiliitis (also XR +ve, fulfilling mNY criteria)	<u>USS:</u> Marked Achilles enthesitis PD +ve	<u>MRI:</u> Bilateral sacroiliitis	<u>MRI:</u> Bilateral sacroiliitis <u>USS:</u> Knee synovitis, hand flexor tenosynovitis, PD +ve	<u>USS:</u> elbow, knee and wrist synovitis, common extensor enthesitis.
HLA-B27	N	NA	NA	N	Y	NA	N	N	N	N	NA
Smoker (cpd)	15	NA	NA	25	N	N	N	N	N	N	N
EAMs (Uveitis, PsO)	N	N	PsO	N	PsO	N	N	N	PsO	N	PsO
IBD type/ activity	CD/ Low/ controlled	IC/ Low/ controlled	CD/NA	CD/ Active (high)	UC/ Low/ controlled	UC/ Low/ controlled	IC/ Low/ controlled	CD/ Active (moderate)	UC/ Low/ controlled	CD/Active (high)	UC/ Low/ controlled
CRP at flare (mg/l)	216	<5	<5	24	24	28	55	68	33	80	88
Concomitant DMARD	MTX 15mg o.w	AZA 150mg o.d	Pred 0.5mg o.d	None	None	Pred 4mg o.d	None	None	MTX 7.5mg o.w	None	Pred 15mg o.d
TNFi failure	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N
Previous TNFi /DMARDs	IFX ADA CZP	ADA IFX	AZA IFX ADA	IFX ADA	MSZ CYSP IFX ADA	6-MP AZA ADA	IFX	6-MP, AZA	IFX Secukinumab ADA	IFX CZP GLM	None
Vedolizumab discontinued	Y	Y	Y	Y	Y	Y	Y	Y	N	N	Y
Treatment change	GLM	Patient declined treatment for SpA.	Bilateral sacroiliac joint injection and switched to UST	CZP	CZP: intolerance. SZP: intolerance. Switched to GLM.	TOFA+ ZOL	ADA	ADA+Pred	VDZ +Pred 10mg o.d + Apremilast; developed significant depression.	ETN+ VDZ	ADA

Outcome	Moderate IBD and SpA activity at 6 months, CRP 58 BASDAI 6.9 (previous 8.8)	IBD in remission at 6 months (colonoscopy normal) SpA outcomes: NA	NA	IBD: controlled SpA: mild to moderate activity at 6 months, CRP 19	IBD in remission. SpA activity is moderate at 6 months.	Periostitis and enthesitis resolved at 6 months.	Mild axSpA. Skin and perSpA in remission at 1 month.	Achilles enthesitis much improved. Moderate CD activity at 1 month	to MTX 7.5mg o.w. IBD/ SpA /Skin PsO all well controlled at 6 months.	IBD and SpA in drug controlled remission at 6 months.	NA
---------	---	--	----	--	---	--	--	--	---	---	----

Y: yes; N: no; NA: not available; cpd: cigarettes per day; EAMs :extra-articular manifestations; nr: non-radiographic; Osteitis or Enthesitis: + mild, ++ moderate, +++ severe; o.d: once daily; o.w: once weekly; CD: Crohn's disease; UC: ulcerative colitis; IC: intermediate colitis; IRLs: inflammatory Romanus corner lesions; PD: Power Doppler; XR: X-ray; TNFi: tumour necrosis factor inhibitor; ADA: adalimumab; CZP: certolizumab pegol; CYP: cyclosporine; GLM: golimumab; IFX: infliximab; MSZ: mesalazine; MTX: methotrexate; Pred :prednisolone; TOFA: tofacitinib; UST: ustekinumab; VDZ: vedolizumab; ZOL: zolendronate.



A




C



B



D



E

